Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress

The United States pays more for medical care than any other nation in the world, including for prescription drugs. These costs are inequitably distributed, as individuals from underrepresented racial and ethnic groups in the United States experience the highest costs of care and unequal access to hi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of health politics, policy and law policy and law, 2022-12, Vol.47 (6), p.709-729
Main Authors: Chalasani, Rohan, Krishnamurthy, Sudarshan, Suda, Katie J., Newman, Terri V., Delaney, Scott W., Essien, Utibe R.
Format: Article
Language:English
Subjects:
Access
Drug therapy
Drugs
Ethnic groups
Ethnicity
Health care expenditures
Health care policy
Health Policy
Health services
Health Services Accessibility
Humans
Inequality
Infrastructure
Medical treatment
Medicine
Medicine and Health
Minority & ethnic groups
Patients
Pharmacology
Political Science
Politics
Prescription drugs
Public Health and Health Policy
Public Policy
Quality of care
Race
Racism
Social Class
Social Determinants of Health
Social policy
Socioeconomic factors
Socioeconomic status
Socioeconomics
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The United States pays more for medical care than any other nation in the world, including for prescription drugs. These costs are inequitably distributed, as individuals from underrepresented racial and ethnic groups in the United States experience the highest costs of care and unequal access to high-quality, evidence-based medication therapy. refers to equity in access to pharmacotherapies or ensuring that all patients, regardless of race and ethnicity, socioeconomic status, or availability of resources, have access to the highest quality of pharmacotherapy required to manage their health conditions. Herein the authors describe the urgent need to prioritize pharmacoequity. This goal will require a bold and innovative examination of social policy, research infrastructure, patient and prescriber characteristics, as well as health policy determinants of inequitable medication access. In this article, the authors describe these determinants, identify drivers of ongoing inequities in prescription drug access, and provide a framework for the path toward achieving pharmacoequity.
ISSN:0361-6878
1527-1927
DOI:10.1215/03616878-10041135